Quick answer
As of September 26, 2026, GLP-1 medication is a reasonable option to discuss with a physician if you are an adult with obesity, or with overweight plus a weight-related condition, and nothing on the label rules you out: no personal or family history of medullary thyroid carcinoma, no Multiple Endocrine Neoplasia syndrome type 2, and no pregnancy planned soon. Pancreatitis, gallbladder disease, or severe gastroparesis calls for careful review, and combining a GLP-1 with insulin or a sulfonylurea raises the risk of low blood sugar. Only a licensed physician can decide after reviewing your full history, and the honest expectation is a tool alongside nutrition, activity, and sleep, not a shortcut. Compounded medications are not FDA-approved as final products.
GLP-1 receptor agonists have become one of the most talked-about treatments in weight management. But like any medical intervention, they're not for everyone. Before starting treatment, it's important to have an honest conversation with your healthcare provider about whether GLP-1 medication is appropriate for your specific situation.
Here are the key questions to ask, and what you should know before your consultation.
Am I a Candidate for GLP-1 Treatment?
GLP-1 medications are generally prescribed for adults who meet certain clinical criteria. While every provider may have slightly different guidelines, the standard benchmarks include:
- BMI of 30 or higher (classified as obesity)
- BMI of 27 or higher with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea
- Previous attempts at weight loss through diet and exercise that haven't achieved lasting results
It's worth noting that BMI is just one screening tool, your doctor will also consider your overall health history, family history, and individual risk factors.
Why BMI Matters (and Its Limitations)
BMI provides a quick snapshot of whether your weight falls within a range that may benefit from medical intervention. Our BMI calculator for GLP-1 eligibility shows where your number falls and what it does and does not decide. However, it doesn't account for muscle mass, bone density, or body composition. That's why a comprehensive medical evaluation is essential, not just a number on a chart.
What Are the Potential Contraindications?
Not everyone can safely take GLP-1 medications. Be sure to discuss the following with your doctor:
- Personal or family history of medullary thyroid carcinoma (MTC): GLP-1 receptor agonists carry a boxed warning related to thyroid C-cell tumors observed in animal studies. If you or a close family member has had MTC, these medications are generally not recommended.
- History of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): This genetic condition is a contraindication for GLP-1 use.
- Pancreatitis: If you have a history of pancreatitis, your doctor will need to weigh the risks carefully.
- Gallbladder disease: GLP-1 medications may increase the risk of gallbladder-related issues in some patients.
- Severe gastrointestinal conditions: Conditions like gastroparesis (delayed stomach emptying) may be worsened by GLP-1 medications.
- Pregnancy or breastfeeding: GLP-1 medications are not recommended during pregnancy or while breastfeeding.
What Should I Expect in Terms of Results?
This is one of the most important questions, and one where realistic expectations matter.
The pivotal trials of the FDA-approved products studied branded medicines at set doses in selected populations. Their averages are published and worth reading in the publications themselves, and they are not a forecast for you and do not transfer to compounded preparations. What those programmes established is that the mechanism produces clinically meaningful change for many people, which is a different statement from any single headline average. These trials studied the FDA-approved brand products; compounded preparations have not been studied in comparable trials, and individual results vary.
However, individual results vary significantly. Factors that influence your outcome include:
- Your starting weight and metabolic profile
- How consistently you take the medication
- Your dietary habits and physical activity level
- Genetic factors that influence how your body responds to the medication
- Whether you're also managing other health conditions
The key takeaway: GLP-1 medication is not a magic pill. It's a powerful tool that works best when combined with sustainable lifestyle changes.
What Questions Should I Bring to My Doctor?
Here's a checklist of questions to discuss during your consultation:
- "Based on my health history, am I a good candidate for GLP-1 treatment?". Let your doctor evaluate your complete picture, not just your BMI.
- "Are there any drug interactions I should be aware of?". If you're taking other medications (especially insulin, sulfonylureas, or blood thinners), your doctor needs to check for interactions.
- "What's the typical dose escalation schedule?". GLP-1 medications are started at a low dose and gradually increased. Understanding the timeline helps set expectations.
- "What side effects should I watch for?". Common side effects include nausea, constipation, and decreased appetite. Most are mild and temporary, but knowing what to expect reduces anxiety.
- "How will my progress be monitored?". A good provider will schedule regular check-ins to track your weight, metabolic markers, and overall well-being.
- "What happens if I stop taking the medication?". Research suggests that weight regain is possible after discontinuation. Discuss long-term planning with your provider.
- "Is compounded semaglutide an option for me?". Ask what the all-in monthly price covers. Compounded formulations, prepared by state-licensed pharmacies, are a separate self-pay category and are not FDA-approved as final products.
Who Should NOT Start GLP-1 Without Medical Supervision?
To be clear: GLP-1 medications should always be prescribed and monitored by a licensed healthcare provider. However, certain groups need especially careful evaluation:
- Patients with a history of eating disorders
- Patients with severe kidney or liver disease
- Patients over 65, who may need adjusted dosing
- Patients with a history of suicidal ideation (some medications in this class have been studied for mental health effects)
What should any provider's evaluation include?
Whatever provider you choose, the consultation should be conducted by a licensed physician who evaluates your complete health profile, not an AI chatbot or automated prescribing. A real doctor reviews your case and makes a clinical determination, which may include a phone or video visit where your state's telehealth rules require one or where the physician determines it is needed. If GLP-1 treatment is not appropriate for you, a careful provider says so and discusses alternatives with you.
What the primary sources say
- DailyMed, WEGOVY (semaglutide) prescribing information, Medication Guide (accessed September 26, 2026): "Do not use WEGOVY if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)."
- DailyMed, ZEPBOUND (tirzepatide) prescribing information, section 1 Indications and Usage (accessed September 26, 2026): "to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition"
- National Institute of Diabetes and Digestive and Kidney Diseases, Prescription Medications to Treat Overweight & Obesity (accessed September 26, 2026): "Weight management medications aren't for everyone with a high BMI. If you are overweight or have obesity, you might be able to lose weight with a lifestyle program that changes your behaviors and improves your eating and physical activity habits."
- U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers (accessed September 26, 2026): "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any medication. Individual results may vary.
Related 2026 guides
Frequently Asked Questions
Who is a good candidate for GLP-1 weight loss medication?
Standard FDA labeling for weight-management GLP-1s targets adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. Good candidates are also patients without contraindications (no personal or family history of medullary thyroid carcinoma, no multiple endocrine neoplasia syndrome type 2, no prior pancreatitis, no severe gastroparesis, not pregnant or planning pregnancy soon), and patients who are prepared to maintain the dietary and lifestyle changes that maximize results.
Who should not take GLP-1 medications?
Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, prior episodes of pancreatitis, severe gastroparesis, and pregnancy or planned pregnancy in the near term. Patients with severe kidney or gallbladder disease, active diabetic retinopathy, or who are breastfeeding should discuss risk-benefit with a physician before starting. A US-licensed physician makes the final eligibility determination after reviewing your full medical history.
What questions should I ask my doctor before starting GLP-1?
Ask: Which medication and dose are you starting me on and why? What are the expected side effects in the first 4 to 8 weeks? When and how do we escalate the dose? What signs would make us pause or stop treatment? How will we monitor for serious side effects (pancreatitis, gallbladder disease, kidney function)? What is the realistic expected weight reduction and time horizon? What is the long-term plan, including maintenance after target weight is reached? How do we handle hair shedding, fatigue, or mood changes if they happen?
Can I take GLP-1 if I don't have diabetes?
Yes, for weight management. Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management in non-diabetic adults who meet the BMI criteria. Compounded semaglutide and tirzepatide may also be prescribed by US-licensed physicians for weight management in non-diabetic adults at appropriate doses. Eligibility is decided by your physician based on BMI, weight-related health conditions, and overall medical history.
What if I don't qualify for GLP-1 based on BMI?
If your BMI is below 27, GLP-1 medications are generally not appropriate as a weight loss tool. Modest weight reduction is usually better pursued through nutrition, strength training, sleep optimization, and behavioral support. If your BMI is in the 25 to 27 range with a weight-related condition, a physician can review whether off-label GLP-1 prescribing is appropriate (it sometimes is, depending on clinical context). The honest answer is that GLP-1 is most beneficial for patients who meet labeled criteria and who would otherwise be unable to reach a healthy weight through lifestyle alone.
What should I bring to a consultation about GLP-1 medication?
Bring a complete list of current medications and supplements, especially insulin, sulfonylureas, and blood thinners, plus your personal and family medical history with attention to thyroid cancer, endocrine syndromes, pancreatitis, gallbladder disease, and digestive conditions. Note previous weight-loss attempts and what happened, any plans for pregnancy, and your questions about monitoring and long-term planning. The more complete the picture, the better the physician can judge whether treatment is appropriate for you.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.WEGOVY (semaglutide) injection, tablet: Prescribing Information and Medication Guide (DailyMed) · DailyMed, U.S. National Library of Medicine (Novo Nordisk label) · accessed
- 2.ZEPBOUND (tirzepatide) injection: Prescribing Information (DailyMed), section 1 Indications and Usage · DailyMed, U.S. National Library of Medicine (Eli Lilly label) · accessed
- 3.Prescription Medications to Treat Overweight & Obesity · National Institute of Diabetes and Digestive and Kidney Diseases, NIH · accessed
- 4.Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them